AmMax is developing first-in-class or best-in-class therapeutics for a number of diseases with significant unmet needs including TGCT, IPF and PKD. Clinical trials are needed to assess the efficacy and safety of these experimental therapies.
AmMax is initiating a multi-center, global Phase 2 study to assess the efficacy and safety of AMB-051 in patients with TGCT.
Study Title: An adaptive, multicenter, open-label study to evaluate the safety, efficacy, and pharmacokinetics of intra-articular AMB-05X injection in subjects with tenosynovial giant cell tumor of the knee.
If you are interested in participating in the trial or have questions, please feel free to contact us at email@example.com.